766 related articles for article (PubMed ID: 12065746)
1. Biallelic inactivation of BRCA2 in Fanconi anemia.
Howlett NG; Taniguchi T; Olson S; Cox B; Waisfisz Q; De Die-Smulders C; Persky N; Grompe M; Joenje H; Pals G; Ikeda H; Fox EA; D'Andrea AD
Science; 2002 Jul; 297(5581):606-9. PubMed ID: 12065746
[TBL] [Abstract][Full Text] [Related]
2. Direct interaction of the Fanconi anaemia protein FANCG with BRCA2/FANCD1.
Hussain S; Witt E; Huber PA; Medhurst AL; Ashworth A; Mathew CG
Hum Mol Genet; 2003 Oct; 12(19):2503-10. PubMed ID: 12915460
[TBL] [Abstract][Full Text] [Related]
3. Cellular characterization of cells from the Fanconi anemia complementation group, FA-D1/BRCA2.
Godthelp BC; van Buul PP; Jaspers NG; Elghalbzouri-Maghrani E; van Duijn-Goedhart A; Arwert F; Joenje H; Zdzienicka MZ
Mutat Res; 2006 Oct; 601(1-2):191-201. PubMed ID: 16920162
[TBL] [Abstract][Full Text] [Related]
4. A cross-linker-sensitive myeloid leukemia cell line from a 2-year-old boy with severe Fanconi anemia and biallelic FANCD1/BRCA2 mutations.
Meyer S; Fergusson WD; Oostra AB; Medhurst AL; Waisfisz Q; de Winter JP; Chen F; Carr TF; Clayton-Smith J; Clancy T; Green M; Barber L; Eden OB; Will AM; Joenje H; Taylor GM
Genes Chromosomes Cancer; 2005 Apr; 42(4):404-15. PubMed ID: 15645491
[TBL] [Abstract][Full Text] [Related]
5. Coinheritance of BRCA1 and BRCA2 mutations with Fanconi anemia and Bloom syndrome mutations in Ashkenazi Jewish population: possible role in risk modification for cancer development.
Koren-Michowitz M; Friedman E; Gershoni-Baruch R; Brok-Simoni F; Patael Y; Rechavi G; Amariglio N
Am J Hematol; 2005 Mar; 78(3):203-6. PubMed ID: 15726604
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of Fanconi Anemia genes in familial breast cancer predisposition.
Seal S; Barfoot R; Jayatilake H; Smith P; Renwick A; Bascombe L; McGuffog L; Evans DG; Eccles D; Easton DF; Stratton MR; Rahman N;
Cancer Res; 2003 Dec; 63(24):8596-9. PubMed ID: 14695169
[TBL] [Abstract][Full Text] [Related]
7. Cytogenetic instability in ovarian epithelial cells from women at risk of ovarian cancer.
Pejovic T; Yates JE; Liu HY; Hays LE; Akkari Y; Torimaru Y; Keeble W; Rathbun RK; Rodgers WH; Bale AE; Ameziane N; Zwaan CM; Errami A; Thuillier P; Cappuccini F; Olson SB; Cain JM; Bagby GC
Cancer Res; 2006 Sep; 66(18):9017-25. PubMed ID: 16982743
[TBL] [Abstract][Full Text] [Related]
8. Genetic reversion in an acute myelogenous leukemia cell line from a Fanconi anemia patient with biallelic mutations in BRCA2.
Ikeda H; Matsushita M; Waisfisz Q; Kinoshita A; Oostra AB; Nieuwint AW; De Winter JP; Hoatlin ME; Kawai Y; Sasaki MS; D'Andrea AD; Kawakami Y; Joenje H
Cancer Res; 2003 May; 63(10):2688-94. PubMed ID: 12750298
[TBL] [Abstract][Full Text] [Related]
9. The interplay of Fanconi anemia proteins in the DNA damage response.
Wang X; D'Andrea AD
DNA Repair (Amst); 2004; 3(8-9):1063-9. PubMed ID: 15279794
[TBL] [Abstract][Full Text] [Related]
10. Lower level of BRCA2 protein in heterozygous mutation carriers is correlated with an increase in DNA double strand breaks and an impaired DSB repair.
Arnold K; Kim MK; Frerk K; Edler L; Savelyeva L; Schmezer P; Wiedemeyer R
Cancer Lett; 2006 Nov; 243(1):90-100. PubMed ID: 16448746
[TBL] [Abstract][Full Text] [Related]
11. Tetratricopeptide-motif-mediated interaction of FANCG with recombination proteins XRCC3 and BRCA2.
Hussain S; Wilson JB; Blom E; Thompson LH; Sung P; Gordon SM; Kupfer GM; Joenje H; Mathew CG; Jones NJ
DNA Repair (Amst); 2006 May; 5(5):629-40. PubMed ID: 16621732
[TBL] [Abstract][Full Text] [Related]
12. The molecular biology of Fanconi anemia.
Tamary H; Bar-Yam R; Zemach M; Dgany O; Shalmon L; Yaniv I
Isr Med Assoc J; 2002 Oct; 4(10):819-23. PubMed ID: 12389351
[TBL] [Abstract][Full Text] [Related]
13. BRCA1 and BRCA2 mutation status and tumor characteristics in male breast cancer: a population-based study in Italy.
Ottini L; Masala G; D'Amico C; Mancini B; Saieva C; Aceto G; Gestri D; Vezzosi V; Falchetti M; De Marco M; Paglierani M; Cama A; Bianchi S; Mariani-Costantini R; Palli D
Cancer Res; 2003 Jan; 63(2):342-7. PubMed ID: 12543786
[TBL] [Abstract][Full Text] [Related]
14. Hematopoietic dysfunction in a mouse model for Fanconi anemia group D1.
Navarro S; Meza NW; Quintana-Bustamante O; Casado JA; Jacome A; McAllister K; Puerto S; Surrallés J; Segovia JC; Bueren JA
Mol Ther; 2006 Oct; 14(4):525-35. PubMed ID: 16859999
[TBL] [Abstract][Full Text] [Related]
15. X-linked inheritance of Fanconi anemia complementation group B.
Meetei AR; Levitus M; Xue Y; Medhurst AL; Zwaan M; Ling C; Rooimans MA; Bier P; Hoatlin M; Pals G; de Winter JP; Wang W; Joenje H
Nat Genet; 2004 Nov; 36(11):1219-24. PubMed ID: 15502827
[TBL] [Abstract][Full Text] [Related]
16. The Fanconi anaemia group G gene FANCG is identical with XRCC9.
de Winter JP; Waisfisz Q; Rooimans MA; van Berkel CG; Bosnoyan-Collins L; Alon N; Carreau M; Bender O; Demuth I; Schindler D; Pronk JC; Arwert F; Hoehn H; Digweed M; Buchwald M; Joenje H
Nat Genet; 1998 Nov; 20(3):281-3. PubMed ID: 9806548
[TBL] [Abstract][Full Text] [Related]
17. Fanconi anaemia genes and susceptibility to cancer.
Mathew CG
Oncogene; 2006 Sep; 25(43):5875-84. PubMed ID: 16998502
[TBL] [Abstract][Full Text] [Related]
18. [Complex role of the FA proteins in providing genome stability].
Kluzek K; Zdzienicka MZ
Postepy Biochem; 2005; 51(4):387-94. PubMed ID: 16676573
[TBL] [Abstract][Full Text] [Related]
19. Inducibility of nuclear Rad51 foci after DNA damage distinguishes all Fanconi anemia complementation groups from D1/BRCA2.
Godthelp BC; Wiegant WW; Waisfisz Q; Medhurst AL; Arwert F; Joenje H; Zdzienicka MZ
Mutat Res; 2006 Feb; 594(1-2):39-48. PubMed ID: 16154163
[TBL] [Abstract][Full Text] [Related]
20. Impaired removal of DNA interstrand cross-link in Nijmegen breakage syndrome and Fanconi anemia, but not in BRCA-defective group.
Tsuchida K; Komatsu K
Cancer Sci; 2008 Nov; 99(11):2238-43. PubMed ID: 18771529
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
